EQT to Acquire QIAGEN in 10.8 Billion Euro All-Cash Offer
Start here
Swedish private equity firm EQT has launched a voluntary public all-cash offer for Dutch molecular diagnostics company QIAGEN through its indirectly controlled Crown NL Bidco B.V., at 46.50 euros per share. The deal gives QIAGEN an enterprise value of about 10.8 billion euros, including net debt of about 1.1 billion US dollars and an equity value of about 9.6 billion euros. EQT manages 354 billion euros in assets and has invested more than 30 billion euros in healthcare, with past holdings including Galderma, Parexel and Aldevron. The offer has been announced and awaits shareholder acceptance before the takeover can be completed.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickEQT to Acquire QIAGEN in All-Cash Deal Valued at About 10.8 Billion Euros
Swedish private equity firm EQT announced a voluntary public all-cash offer for Dutch molecular diagnostics company QIAGEN through its indirectly controlled Crown NL Bidco B.V., at 46.50 euros per share, for an enterprise value of about 10.8 billion euros (including net debt of about 1.1 billion US dollars and equity value of about 9.6 billion euros). EQT manages 354 billion euros in assets, has invested more than 30 billion euros in healthcare, and its past portfolio includes Galderma, Parexel and Aldevron.
Heat trend for this story
Heat now 9·Peak in the comparable set 9 (Oct 22 23:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.